Nestle Health Science enters microbiome research venture

929c1134-8d44-4139-8110-035684bd4b33articleimage.jpg

13 Jul 2017 --- Nestlé Health Science and Enterome are establishing Microbiome Diagnostics Partners (MDP), in an attempt to lead the development and commercialization of innovative microbiome-based diagnostics with the potential to transform therapeutic approaches across health conditions such as inflammatory bowel diseases (IBD) and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.

“Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition. We also see new opportunities for personalized nutrition both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics,” says Greg Behar, CEO of Nestlé Health Science.

According to the companies, MDP will initially aim to boost Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). The current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined Dx tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.

The companies announced that Microbiome Diagnostics Partners is to be a 50:50 joint venture between Enterome and Nestlé Health Science. Prometheus (a Nestlé Health Science Company) will contribute its Diagnostics (Dx) development and commercialization expertise. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of Dx in all therapeutic areas except immuno-oncology. 

Nestlé Health Science will reportedly invest €20 million in return for its 50 percent stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities.

Commenting on the move, Behar says, “Microbiome Diagnostics Partners is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics (Dx), nutritional therapies (Nx) and therapeutics (Rx).” 

“The formation of Microbiome Diagnostics Partners is an important milestone for Enterome, as it brings together powerful and complementary technologies and capabilities to enable the creation of a new generation of diagnostic and companion diagnostic products. The MDP joint venture will leverage Enterome’s microbiome-based platforms in diagnostic areas, while Enterome will continue to focus on their application for the discovery of novel small molecule therapeutics,” comments Pierre Belichard, CEO of Enterome.

Related Articles

Business News

BASF: “considerable” Q2 earnings growth, but Nutrition & Health sales stall

27 Jul 2017 --- BASF Group has announced that its second quarter sales rose by 12 percent to €16.3 billion (US$19.11 billion) compared with the same period in 2016. The group states that this was largely attributable to higher prices and volumes. Amid higher raw material costs, the company raised sales prices by 7 percent; this was mainly driven by higher prices in the Chemicals segment. Sales volumes increased by 3 percent. Currency effects had a positive impact on sales and, like portfolio effects, accounted for a 1 percent increase.

Regulatory News

Cargill’s erythritol dental health claim rejected by EFSA

27 Jul 2017 --- Cargill cannot prove its EU Article 14 claim submission [disease risk reduction claim] that there is a cause-and-effect relationship between sugar-free hard confectionery with at least 90 percent erythritol and the reduction of dental plaque, according to the European Food Safety Authority (EFSA).

Business News

Algatech eyes Brazil market following Anvisa approval for astaxanthin line

27 Jul 2017 --- Algatechnologies has received Brazilian Health Regulatory Agency (Anvisa) approval for its all-natural astaxanthin AstaPure to be used as a food ingredient. This approval makes Algatech the first astaxanthin supplier to start marketing its clean-label astaxanthin under the AstaPure brand in Brazil. 

Nutrition & Health News

Binge drinking among young US adults not in college increased

27 July 2017 --- Binge drinking rates are finally down among US college students aged 18 to 24, after years of increases, but they are up among those in the same age group who are not in college, according to a study in the July issue of the Journal of Studies on Alcohol and Drugs. The same study also found that alcohol-related hospitalizations and overdose deaths have increased generally among 18- to 24-year-olds.

Business News

Food and health startups get chance to impress in Innovation Challenge

27 Jul 2017 --- Innovative ingredient projects, carried out by startups that have brought something completely new and unexpected to the food and health markets, will be rewarded as part of the Startup Innovation Challenge during the next Fi Europe & Ni show from November 28 to 30 this year.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestle-health-science-enters-microbiome-research-venture.html